stockrowGlaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) Return on invested capital
Glaukos Corporation's return on invested capital over the twelve months to 30 September 2026 was −24.6%, up 3.4 percentage points from fiscal 2025 (−28.0%). Over the past ten years it has ranged from −47.0% (fiscal 2015) to 12.4% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Medical Devices industry median of −5.27% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −28.0% | (13.22) |
| FY2024 | −14.8% | 0.70 |
| FY2023 | −15.5% | (5.79) |
| FY2022 | −9.69% | (5.78) |
| FY2021 | −3.91% | 11.14 |
| FY2020 | −15.1% | (9.41) |
| FY2019 | −5.64% | 18.71 |
| FY2018 | −24.4% | (16.92) |
| FY2017 | −7.43% | (19.80) |
| FY2016 | 12.4% | 59.40 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PODD Insulet Corporation compare | 18.8% |
| PEN Penumbra, Inc. compare | 12.7% |
| GMED Globus Medical, Inc. compare | 8.86% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.66% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BIO.B Bio-Rad Laboratories, Inc. compare | −0.44% |
| BIO Bio-Rad Laboratories, Inc. compare | −0.44% |
| BRKR Bruker Corporation compare | −1.12% |
| GKOS Glaukos Corporation | −24.6% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on GKOS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement